United Therapeutics Corporation

UTHR · NASDAQ

United Therapeutics is a profitable rare-disease biotech with an unusually strong cash baseline. The hard question is not whether the company currently earns money; it is whether pulmonary hypertension concentration, lifecycle management and pipeline investment can keep compounding without a product-cycle break.

Follow Add to Watchlist Ask Question

NASDAQ UTHR Coverage Bootstrap United Therapeutics Corporation

Latest ReportMay 20, 2026United Therapeutics: the rare-disease cash engine has to outrun concentration riskView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.